Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virtual visits after heart failure hospitalization: a lifeline or a gamble?

NCT ID NCT05724433

Disease control Sponsor: Population Health Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether a 3-month program of virtual visits and remote monitoring can improve recovery in adults recently hospitalized for heart failure. Participants receive either virtual heart failure care or routine care, and researchers track medication optimization, health status, and outcomes like death or readmission. The goal is to see if this digital approach can help patients get back on track and stay healthier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Virtual heart failure care (virtual visits and remote monitoring)
What this could lead to
If effective, virtual care could become a standard way to help heart failure patients recover better after a hospital stay, potentially reducing deaths and readmissions.
What could go wrong
The trial is still testing this approach, and results may not show clear benefits. Virtual care may not suit all patients, and there are risks of technical issues or reduced personal interaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 891 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients ≥ 18 years old who: 1. Are being discharged after hospitalization or urgent visit for HF as 1. a primary diagnosis or 2. significant complication (prolonging length of stay) of another diagnosis OR Have been referred for an initial consult at a cardiology clinic within 1 week of hospitalization or urgent visit for HF as a primary or secondary diagnosis, as described above. 2. Have left ventricular ejection fraction (LVEF) \< 50% within the preceding 3 months. 3. Have NT-proBNP of \> 900 pg/ml during hospital admission or within 7 days after discharge from the ED 4. Have a mailing address for patient or caregiver 5. Provide verbal consent Exclusion Criteria: 1. Died or left hospital before medically advised hospital discharge 2. Unable to self-assess or communicate symptoms (e.g. clinically evident dementia) 3. Unable to engage with digital health technology or follow up 4. Severe valve disease 5. Recipient of or on waiting list for LVAD or cardiac transplant 6. Complex congenital heart disease, hypertrophic obstructive cardiomyopathy, or amyloid cardiomyopathy 7. Severe lung disease with symptoms on minimal exertion, forced expiratory volume during 1 second (FEV1) \< 1 litre, severe pulmonary hypertension with RVSP \> 60 mm Hg, or on home oxygen 8. Severe kidney disease (persistent eGFR \< 30 mL/min/1.73m2) 9. Active malignancy 10. Receiving palliative care or expected life expectancy \< 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fattouma Bourguiba Hospital

    RECRUITING

    Monastir, Tunisia

  • Hamilton General Hospital

    RECRUITING

    Hamilton, Ontario, L8L 2X2, Canada

  • Hedi Chaker Hospital

    RECRUITING

    Sfax, Tunisia

  • Juravinski Hospital Cancer Centre

    RECRUITING

    Hamilton, Ontario, L8V 5C2, Canada

  • Military Hospital

    RECRUITING

    Tunis, Tunisia

  • Sahloul Hospital

    RECRUITING

    Sousse, Tunisia

  • St. Joseph's Healthcare Hamilton

    RECRUITING

    Hamilton, Onatrio, L8N 4A6, Canada

  • Thunder Bay Regional Health Sciences Centre

    NOT_YET_RECRUITING

    Thunder Bay, Ontario, Canada

  • Unity Health Toronto

    RECRUITING

    Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.